"The other thing is that any time BP is involved they leak and we read about it in the paper and we haven't seen anything so far. Would have thought the drums would have been beating over the weekend if they were." - haha, an excellent observation.
I agree with your points, I think there is unlikely to be a CR. I stick to the views I shared previously that the FDA have suggest that PAR implement some additional measures which will come at a small cost, but will also increase the timeframes which is what they are assessing.
In an earlier announcement from PAR, they stated that: "The agency also provided its suggested mitigation strategies to address its positions and questions, which included further detailed clinical monitoring."
I would not be surprised if this might be say, monitoring for longer periods how long it might take for the effects of PPS to wear off, longer periods between injections etc etc. They're just examples, but you get the picture - the FDA might just be wanting to ensure they can get a fuller picture of the potential ways in which it can be administered and how it could affect patient outcomes.
For long term investors, having the trials go for a bit longer is probably not going to faze them much, but I'm sure it'll give the people trying to make a quick buck shorting this jump out to tell us all the world is ending.
Anyway, all this is just academic speculation for entertainment with no real consequence - we're all locked in and we'll find out in a few hours!
Good luck.
PAR Price at posting:
$2.22 Sentiment: None Disclosure: Held
(20min delay)